ACTG 328--RECOMBINANT HUMAN IL 2 BY IV OR SC IN HIV PATIENTS ON HAART

ACTG 328——在接受 HAART 治疗的 HIV 患者中通过静脉注射或皮下注射重组人 IL 2

• 批准号: 6219931
• 负责人: GILDON N BEALL
• 金额: $ 0.1万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6219931
• 关键词: AIDS therapy; HIV infections; clinical research; drug administration routes; helper T lymphocyte; human subject; human therapy evaluation; immunotherapy; interleukin 2; intravenous administration; recombinant proteins

Highly active antiretroviral treatment (HAART) of HIV infection is associated with dramatic fall in the amount of HIV in the blood. The effects on the immune system are positive but less dramatic. Restoration of the immune system is now a goal of chronic HIV therapy. Interleukin-2 is a substance which is naturally produced by the body's CD4 cells. People with HIV-1 infection do not produce enough IL-2. IL-2 has been shown to increase CD4 cells in HIV-1 patients by 2-4fold. Trials with intravenous IL-2 produced much toxicity in theform of "flu" symptoms.

艾滋病毒感染的高效抗逆转录病毒治疗（HAART）与血液中艾滋病毒数量的急剧下降有关。 对免疫系统的影响是积极的，但不那么引人注目。 免疫系统的恢复现在是慢性HIV治疗的目标。 白细胞介素-2是一种由人体的CD 4细胞自然产生的物质。HIV-1感染者不能产生足够的IL-2。 IL-2已显示使HIV-1患者中的CD 4细胞增加2- 4倍。 静脉注射IL-2的试验产生了很多毒性，表现为“流感”症状。